Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Booming Clinical Research Business Could Trigger Regulatory Overhaul In India

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - Foreign companies could soon get the go-ahead to conduct Phase I studies in India, as part of a national regulatory overhaul spurred on by booming clinical research business, regional experts say
Advertisement

Related Content

Wyeth Defends Clinical Trial Standards After Indian Baby’s Death
Wyeth Defends Clinical Trial Standards After Indian Baby’s Death
India May Soon Allow Outside Phase I Drug Studies
Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances
Piramal Healthcare Buys Rights To Sell Germany’s PlasmaSelect
Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight
India Looks To Model New Central Drug Authority After U.S. FDA
Ranbaxy Board Approves Separate Research Unit, Plans Share Listing This Year
Nicholas Piramal India Inks R&D Deal With Merck
Nicholas Piramal India Inks R&D Deal With Merck
Advertisement
UsernamePublicRestriction

Register

SC068131

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel